Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation. 2008 Jun 03; 117(22):2865-74.